• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 16.48
  • VXN 19.83
  • VXO 17.26
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
CRIS (Curis Inc.)
Last Trade 1.43 Dividend/Share 0 PE Ratio -1.32
Date March 22-2019 Dividend Yield 0.000 Return on Assets -54.74
Change 0.06 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -1.8 Price/Sale 5.912
Ask null LatestEPS Date 2017-12-31 Price to Book 58.01
Volume null EPS ttm -1.080 Institutional % 30.8
Avg Volume 0.17M Shares Outstanding 33.11M Insider % 1.4
Open 1.37 Float 30.83M Short Ratio null
Prev Close 1.37 Return On Equity -221.99 5 Year Change % -0.899
High 1.44 Consensus EPS 0 2 Year Change % -0.904
Low 1.36 No. of Estimate 0.000 1 Year Change % -0.629
52 Week High 3.7935 EPS Surprise $ null YTD Change % 0.741
52 Week Low 0.6 EPS Surprise Percent 0 6 Month Change % -0.133
52 Week Change -62.423 EBITDA 0M 3 Month Change % 0.744
50 Day MA 1.1544 Revenue 0M 1 Month Change % 0.375
200 Day MA Gross Profit 0M 5 Day Change % 0.014
Market Cap 47.35M Cash 0M 30 Day Change % 0.349
Beta 1.99186 Debt 0M Stock Exchange NASDAQ Global Market
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, under collaboration with Genentech, Inc., is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase, epidermal growth factor receptor, and epidermal growth factor receptor 2. In addition, Curis has a development candidate, Debio 0932, which is a Heat Shock Protein 90 or Hsp90 inhibitor. The company holds a license agreement with Debiopharm related to its Hsp90 technologies. Further, it involves in preclinical testing for the development of candidates from its targeted cancer programs. The company was founded in 2000 and is based in Cambridge, Massachusetts.